DaVita (NYSE: DVA) reported Q2 EPS of $2.64, $0.46 better than the analyst estimate of $2.18. Revenue for the quarter came in at $2.92 billion versus the consensus estimate of $2.87 billion.

"We had a strong quarter despite the continued operational challenges presented by the pandemic. Our teammates and nephrologist partners have shown tremendous dedication to caring for our patients, and we have continued to make progress in our efforts to combat COVID-19 over the past several months," said Javier Rodriguez, CEO of DaVita Inc. "Additionally, we accelerated our investments in integrated kidney care capabilities designed to improve patient outcomes, coordinate care, and lower overall costs. We have grown the number of patients under value-based care arrangements to approximately 10% of our U.S. dialysis patient census, and we expect to see significant growth in our integrated kidney care business over the next year."

For earnings history and earnings-related data on DaVita (DVA) click here.